Prelude Therapeutics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Prelude Therapeutics advances its clinical-stage precision oncology pipeline, showcasing positive Phase 1 data for PRT3789 and initiating a Phase 2 trial, while strategically partnering to expand its ADC capabilities.
NASDAQ
Prelude Therapeutics updates its registration rights agreement and files its annual 10-K report, detailing its financial status and clinical development pipeline.